Loading clinical trials...

A Study of LY3471851 in Participants With Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of LY3471851 in Participants With Psoriasis

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis

NCT04119557•Nektar Therapeutics

View on ClinicalTrials.gov

Summary

The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a confirmed diagnosis of psoriasis for at least 6 months
•Have active psoriasis plaques according to study- specific criteria
•Be willing and able to undergo skin biopsies

Exclusion Criteria

•Have received certain topical medications for psoriasis within 14 days prior to baseline
•Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
•Have received LY3471851 previously

Locations (24)

Arkansas Research Trials, LLC

North Little Rock, Arkansas, United States

California Dermatology & Clinical Research Institute

Encinitas, California, United States

Center For Dermatology Clinical Research, Inc.

Fremont, California, United States

Therapeutics Clinical Research

San Diego, California, United States

Clinical Science Institute

Santa Monica, California, United States

Florida Academic Centers Research and Education, LLC

Coral Gables, Florida, United States

Miami Dermatology and Laser Research

Miami, Florida, United States

ForCare Clinical Research

Tampa, Florida, United States

Medical Dermatology Specialists

Sandy Springs, Georgia, United States

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States

Key Dates

Start Date

November 26, 2019

Primary Completion Date

July 21, 2021

Completion Date

July 21, 2021

Last Updated

February 20, 2024

Enrollment

ACTUAL participants

Conditions

Psoriasis

Interventions

Placebo

DRUG

LY3471851

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY3471851 in Participants With Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments